Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TYMS | P04818 | 3/20 | 0.34 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.33 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.31 |
| ▸ | TK1 | P04183 | 1/20 | 0.30 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.30 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374089 | 0.91 | LMNA (0.38) | LMNAALOX12ADRA1ASMN1; SMN2TYMS | |
| SCHEMBL2032440 | 0.88 | L3MBTL1 (0.38) | SMN1; SMN2TYMSTYMPTK1 | |
| SCHEMBL2032439 | 0.80 | L3MBTL1 (0.30) | — | |
| SCHEMBL2027058 | 0.76 | LMNA (0.50) | LMNAALOX12ADRA1ASMN1; SMN2TYMS | |
| SCHEMBL8932052 | 0.75 | TK1 (0.38) | TK1RNASE1 | |
| SCHEMBL8931997 | 0.71 | TK1 (0.35) | TK1 | |
| SCHEMBL1322836 | 0.68 | RNASE1 (0.48) | TK1RNASE1 | |
| SCHEMBL7602581 | 0.68 | LMNA (0.39) | LMNAALOX12ADRA1ASMN1; SMN2TYMS | |
| SCHEMBL8597107 | 0.68 | TK1 (0.46) | TYMSTK1RNASE1 | |
| SCHEMBL2027057 | 0.67 | LMNA (0.49) | LMNAALOX12ADRA1ASMN1; SMN2TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2409980-B1 | 3'modified oligonucleotides containing pseudoisocytosine nucleobase derivatives and applications thereof as primers or probes | APPLIED BIOSYSTEMS LLC (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8268978-B2 | Modified oligonucleotides and applications thereof | APPLIED BIOSYSTEMS, LLC (US) | 2012-09-18 | — | — | US | disclosed |
| EP-2409980-A1 | 3'modified oligonucleotides containing pseudoisocytosine nucleobase derivatives and applications thereof as primers or probes | Applied Biosystems, LLC (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110144319-A1 | Modified Oligonucleotides and Applications Thereof | Life Technologies Corporation (US) | 2011-06-16 | — | — | US | disclosed |
| US-7807376-B2 | Modified oligonucleotides and applications thereof | Life Technologies Corporation (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100112712-A1 | Modified Oligonucleotides and Applications Thereof | Life Technologies Corporation (US) | 2010-05-06 | — | — | US | disclosed |
| EP-1902142-B1 | 3'MODIFIED OLIGONUCLEOTIDES CONTAINING PSEUDOISOCYTOSINE NUCLEOBASE DERIVATIVES AND APPLICATIONS THEREOF AS PRIMERS OR PROBES | APPLIED BIOSYSTEMS LLC (US) | 2010-01-06 | — | — | EP | disclosed |
| US-7585649-B2 | Modified oligonucleotides and applications thereof | APPLIED BIOSYSTEMS, LLC (US) | 2009-09-08 | — | — | US | disclosed |
| US-20090148846-A1 | Modified Oligonucleotides and Applications Thereof | APPLIED BIOSYSTEMS INC. (US) | 2009-06-11 | — | — | US | disclosed |
| US-7414118-B1 | Modified oligonucleotides and applications thereof | APPLIED BIOSYSTEMS INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-7408051-B2 | Modified oligonucleotides and applications thereof | APPLERA CORPORATION (US) | 2008-08-05 | — | — | US | disclosed |
| US-20060084079-A1 | Modified oligonucleotides and applications thereof | APPLERA CORPORATION (US) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144319-A1 | Modified Oligonucleotides and Applications Thereof | RNGTT, POLRMT, POLM | LMNA 1171/4885ALOX12 872/4885ADRA1A 4552/4885 |
| US-20060084079-A1 | Modified oligonucleotides and applications thereof | RNGTT, POLRMT, POLM | LMNA 1171/4885ALOX12 872/4885ADRA1A 4552/4885 |
| US-20100112712-A1 | Modified Oligonucleotides and Applications Thereof | RNGTT, POLRMT, POLM | LMNA 1171/4885ALOX12 872/4885ADRA1A 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.